LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here ...

VUITY, an FDA-approved eye drop for presbyopia, has significant market potential given the growing aging population. With an estimated 128 million Americans affected by presbyopia, VUITY offers a ...

Monovision is the name given to the art and science of fitting contact lenses on a patient who has developed presbyopia. Presbyopia is the unavoidable change in vision that usually occurs at ...

Individuals with mild to moderate presbyopia who were treated with CSF-1 were able to achieve and maintain functional vision for at least 5 hours after two doses, according to a presenter at Academy ...

Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) ...

Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US. AbbVie is recommending Vuity ...

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with ...

LENZ Therapeutics (formerly Presbyopia Therapies) is working on eyedrops containing aceclidine – thought to act like pilocarpine as a miotic agent, reducing eye pressure – showed improvements ...

TD Cowen analyst Stacy Ku initiated coverage of Lenz Therapeutics (LENZ) with a Buy rating and $60 price target The firm cites conviction in ...

ATHENS, Greece — Allogenic corneal inlays can be a safe solution for mild hyperopia and emmetropic presbyopia, according to an expert at the ESCRS winter meeting. The FDA granted fast track ...